FLT3LG and cancer: OVs expressing FLT3L trigger DC and T cell infiltration into the tumor and enhance both antitumoral and antiviral immune responses (42, 59, 60), implicating potential benefits of using FLT3L as an adjuvant to cancer vaccination.